Christopher Titsworth
Family · Fayetteville, ARNPI 1457047144
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,632 of the $8,899 with a category attached, or 85.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- AbbVie$850
- Neurocrine Biosciences, Inc.$830
- Novartis$603
- UCB, Inc.$588
- EMD Serono, Inc.$585
- plus $4K from 25 others
What the payments were for
- Travel & lodging$1,26714%
- Food & beverage$7,63286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 7 | $1,703 |
| AbbVie | 54 | $850 |
| Neurocrine Biosciences, Inc. | 30 | $830 |
| Novartis | 33 | $603 |
| UCB, Inc. | 27 | $588 |
| EMD Serono, Inc. | 21 | $585 |
| SK Life Science, Inc. | 21 | $537 |
| Pfizer | 31 | $455 |
| Eisai Inc. | 8 | $364 |
| Kyowa Kirin, Inc. | 13 | $323 |
| AstraZeneca(2 entities) | 17 | $308 |
| Bristol Myers Squibb | 8 | $218 |
| Lundbeck LLC | 9 | $180 |
| Teva Pharmaceuticals USA, Inc. | 8 | $151 |
| Genentech USA, Inc. | 9 | $131 |
| MDD US Operations, LLC | 6 | $127 |
| ANI Pharmaceuticals, Inc. | 5 | $122 |
| Catalyst Pharmaceuticals, Inc. | 6 | $112 |
| Averitas Pharma Inc. | 3 | $109 |
| Lilly USA, LLC | 2 | $106 |
| Banner Life Sciences, LLC | 5 | $94 |
| Neurelis, Inc. | 4 | $86 |
| Tanabe Pharma America, Inc. | 3 | $68 |
| Amneal Pharmaceuticals LLC | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| TG Therapeutics, Inc. | 1 | $37 |
| Argenx US, Inc. | 2 | $35 |
| Organogenesis Inc. | 1 | $31 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Biogen | 1 | $15 |
| Corium, LLC | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,899 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 19 | $225,453 |
| Kesimpta PenOfatumumab | 17 | $191,671 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $104,108 |
| Nurtec OdtRimegepant Sulfate | 67 | $93,739 |
| Emgality PenGalcanezumab-Gnlm | 64 | $60,803 |
| Austedo XrDeutetrabenazine | 15 | $58,454 |
| Tetrabenazine | 12 | $33,693 |
| BriviactBrivaracetam | 16 | $23,049 |
| QuliptaAtogepant | 18 | $18,929 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $15,003 |
| UbrelvyUbrogepant | 11 | $14,480 |
| Carbamazepine ErCarbamazepine | 39 | $5,156 |
| Primidone | 214 | $3,243 |
| Levetiracetam | 121 | $3,016 |
| Memantine Hcl | 236 | $3,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $151 | $283,90734 claims |
| PfizerNurtec Odt | $455 | $93,73967 claims |
| AbbVieQulipta, Ubrelvy | $850 | $33,40929 claims |
| UCB, Inc.Briviact | $588 | $23,04916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Fayetteville
- Shelby CochranFayetteville$23K
- Margaret OliverFayetteville$12K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.